MyFinsight
Home
Blog
About
Cash and cash
equivalents
$5,596,254
(-82.44%↓ Y/Y)
Prepaid expenses and
other assets
$1,448,939
(-18.35%↓ Y/Y)
Total current assets
$7,045,193
(-79.06%↓ Y/Y)
Prepaid expenses
$1,548,580
(-76.37%↓ Y/Y)
Property and equipment,
net
$176,612
(34.71%↑ Y/Y)
Financing lease
right-to-use assets
$36,828
(-74.22%↓ Y/Y)
Total assets
$8,807,213
(-78.24%↓ Y/Y)
Accumulated deficit
-$233,706,135
(-16.83%↓ Y/Y)
Total liabilities and
stockholders' equity
$8,807,213
(-78.24%↓ Y/Y)
Total stockholders'
equity
-$3,579,739
(-122.43%↓ Y/Y)
Additional paid-in capital
$230,107,941
(6.54%↑ Y/Y)
Common stock, 0.00033
par value,...
$18,455
(19.92%↑ Y/Y)
Total liabilities
$12,386,952
(-49.47%↓ Y/Y)
Total current
liabilities
$12,377,476
(7.34%↑ Y/Y)
Financing lease
obligation-long term
$9,476
(-76.98%↓ Y/Y)
Accounts payable
$6,393,967
(42.17%↑ Y/Y)
Current portion of debt
$4,322,500
(-21.41%↓ Y/Y)
Accrued expenses
$1,629,313
(9.93%↑ Y/Y)
Financing lease
obligation-short term
$31,696
(-38.97%↓ Y/Y)
Back
Back
Balance Sheet
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)
source: myfinsight.com